Predictive Oncology Announces CEO Retirement
September 16 2022 - 5:05PM
Predictive Oncology (NASDAQ: POAI) today announced that J.
Melville (“Mel”) Engle will retire as Chief Executive Officer and
as Chairman and a member of the company’s Board of Directors. To
ensure a smooth transition of his responsibilities, Mr. Engle will
continue to serve in his role through October 31, 2022. Pursuant to
policies regarding leadership succession, the governance committee
of POAI’s Board of Directors is working with a succession plan to
replace Mr. Engle as Chief Executive Officer.
“It has been a privilege to create and lead a team that embraces
innovative ideas that will impact the future of oncology drug
development," said Mr. Engle. “There is great wisdom, energy and
inspirational work going on at Predictive Oncology by people who
are dedicated to the fight against cancer. It is an honor to end my
career here.”
Mr. Engle, 72, has been with POAI since 2016, when he joined the
Board of Directors. He was appointed Chairman of the Board in
January 2020 and was named Chief Executive Officer in March 2021.
He has played an instrumental role in the company’s growth as it
has evolved as a partner to pharmaceutical and biotech companies
involved in oncology drug development. Under his guidance, Mr.
Engle has helped expand the company’s offerings to become a suite
of solutions along the drug development continuum, from early
discovery to clinical trials.
“We appreciate the vision that Mel has brought to the company
and the impact he has made on our strategic positioning, which sets
us up for the next stage of growth,” said Bob Myers, POAI Chief
Financial Officer.
Among his achievements at POAI, Engle led the effort to acquire
zPREDICTA, with the goal to broaden the company’s offerings with
the production of 3D tumor models in oncology drug development.
About Predictive OncologyPredictive Oncology
(NASDAQ: POAI) is a knowledge-driven company focused on applying
artificial intelligence (AI) to develop optimal cancer therapies,
which can lead to more effective treatments and improved patient
outcomes. Through AI, Predictive Oncology uses a biobank of
150,000+ cancer tumors, categorized by patient type, against drug
compounds to help the drug discovery process and increase the
probability of success. The company offers a suite of
solutions for oncology drug development from early discovery to
clinical trials.
Public Relations Contact:Predictive
OncologyTheresa
Ferguson630-566-2003tferguson@predictive-oncology.com
Investor Relations Contact:Landon Capital Keith
Pinder(404) 995-6671kpinder@landoncapital.net
Forward-Looking Statements:Certain matters
discussed in this release contain forward-looking statements. These
forward-looking statements reflect our current expectations and
projections about future events and are subject to substantial
risks, uncertainties and assumptions about our operations and the
investments we make. All statements, other than statements of
historical facts, included in this press release regarding our
strategy, future operations, future financial position, future
revenue and financial performance, projected costs, prospects,
changes in management, plans and objectives of management are
forward-looking statements. The words “anticipate,” “believe,”
“estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target”
and similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Our actual future performance may
materially differ from that contemplated by the forward-looking
statements as a result of a variety of factors including, among
other things, factors discussed under the heading “Risk Factors” in
our filings with the SEC. Except as expressly required by law,
the Company disclaims any intent or obligation to update these
forward-looking statements.
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Apr 2023 to Apr 2024